Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Quinine
Drug ID BADD_D01895
Description An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. The mechanisms of its antimalarial effects are not well understood.
Indications and Usage For the treatment of malaria and leg cramps
Marketing Status approved
ATC Code P01BC01
DrugBank ID DB00468
KEGG ID D08460; D08461
MeSH ID D011803
PubChem ID 3034034
TTD Drug ID D03DDR
NDC Product Code 65162-811
UNII A7V27PHC7A
Synonyms Quinine | Quinimax | Quinine Bisulfate | Bisulfate, Quinine | Quinine Hydrochloride | Hydrochloride, Quinine | Myoquin | Quinamm | Quinbisan | Legatrim | Quinine Lafran | Quinine Sulfate | Sulfate, Quinine | Quinine Sulphate | Sulphate, Quinine | Quinine-Odan | Quinoctal | Surquina | Biquinate | Strema | Quindan | Quinbisul | Quinson | Quinsul
Chemical Information
Molecular Formula C20H24N2O2
CAS Registry Number 72402-53-0
SMILES COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Papule23.03.03.038---
Petechiae01.01.03.002; 23.06.01.003; 24.07.06.004---
Photophobia06.01.01.004; 17.17.02.0060.000734%
Photosensitivity reaction23.03.09.003--
Plasmodium falciparum infection01.03.02.012; 11.06.04.003---
Pre-existing condition improved08.01.03.0430.002495%-
Pruritus23.03.12.001--
Pulmonary oedema02.05.02.003; 22.01.03.003--
Purpura01.01.04.003; 23.06.01.004; 24.07.06.005--
Pyrexia08.05.02.003--
Rash23.03.13.001---
Rash erythematous23.03.13.029---
Rash maculo-papular23.03.13.004--
Rash scarlatiniform23.03.13.006---
Renal failure20.01.03.005---
Restlessness17.02.05.021; 19.11.02.002--
Retinal artery occlusion06.10.01.005; 24.01.07.0030.001835%-
Retinal degeneration06.09.03.0020.002202%-
Retinal depigmentation06.09.03.0040.001101%-
Retinal disorder06.08.03.0050.001101%-
Retinal oedema06.04.06.007; 24.03.07.0060.001101%-
Retinal vascular disorder06.10.01.002; 24.03.07.0020.001101%
Retinopathy06.10.02.001; 24.03.07.0030.001468%
Rhabdomyolysis15.05.05.0020.002202%
Seizure17.12.03.001--
Shock24.06.02.002---
Skin disorder23.03.03.007---
Somnolence17.02.04.006; 19.02.05.0030.001101%
Stevens-Johnson syndrome10.01.01.045; 11.07.01.005; 12.03.01.014; 23.03.01.0070.001101%
Sudden visual loss06.02.10.011; 17.17.01.014---
The 5th Page    First    Pre   5 6 7    Next   Last    Total 7 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene